DK2768521T3 - Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII - Google Patents

Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII Download PDF

Info

Publication number
DK2768521T3
DK2768521T3 DK12772969.7T DK12772969T DK2768521T3 DK 2768521 T3 DK2768521 T3 DK 2768521T3 DK 12772969 T DK12772969 T DK 12772969T DK 2768521 T3 DK2768521 T3 DK 2768521T3
Authority
DK
Denmark
Prior art keywords
leu
ser
lys
thr
glu
Prior art date
Application number
DK12772969.7T
Other languages
English (en)
Inventor
Sabine Zollner
Hubert Metzner
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2768521T3 publication Critical patent/DK2768521T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01025—Beta-mannosidase (3.2.1.25), i.e. mannanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Farmaceutisk præparat, omfattende Faktor VIII, et sulfateret glykosami-noglykan, og en hyaluronidase.
2. Farmaceutisk præparat ifølge krav 1, hvorved Faktor VIII, det sulfaterede glykosaminoglykan, og hyaluronidasen indeholdes i samme sammensætning.
3. Farmaceutisk præparat ifølge krav 1, hvorved henholdsvis Faktor VIII, det sulfaterede glykosaminoglykan og hyaluronidasen er tilvejebragt i separat dosisform i det farmaceutiske præparat.
4. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvorved hyaluronidasen er human hyaluronidase.
5. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvorved det sulfaterede glykosaminoglykan er et heparin.
6. Farmaceutisk præparat ifølge krav 5, hvorved heparinet er ufraktioneret heparin.
7. Faktor VIII til anvendelse ved behandling eller profylakse af en blødningsforstyrrelse, hvorved behandlingen eller profylaksen omfatter indgivelse af et sulfateret glukosaminoglykan og af en hyaluronidase.
8. Faktor VIII til anvendelse ifølge krav 7, hvorved Faktor VIII er human Faktor VIII.
9. Faktor VIII til anvendelse ifølge enten krav 7 eller krav 8, hvorved hyaluronidasen er en human hyaluronidase.
10. Faktor VIII til anvendelse ifølge et hvilket som helst af kravene 7 til 9, hvorved det sulfaterede glykosaminoglykan er et heparin.
11. Faktor VIII til anvendelse ifølge et hvilket som helst af kravene 7 til 10, hvorved blødningsforstyrrelsen er hæmofili A.
12. Faktor VIII til anvendelse ifølge et hvilket som helst af kravene 7 til 11, hvorved Faktor VIII, det sulfaterede glukosaminoglykan og hyaluronidasen indgives samtidig.
13. Faktor VIII til anvendelse ifølge et hvilket som helst af kravene 7 til 11, hvorved Faktor VIII, det sulfaterede glukosaminoglykan og hyaluronidasen indgives separat.
14. Faktor VIII til anvendelse ifølge et hvilket som helst af kravene 7 til 13, hvorved behandlingen eller profylaksen omfatter ikke-intravenøs indgivelse af Faktor VIII, sulfateret glykosaminoglykan og hyaluronidase.
15. Faktor VIII til anvendelse ifølge krav 14, hvorved den ikke-intravenøse indgivelse er subkutan injektion, intramuskulær injektion eller intradermal injektion.
DK12772969.7T 2011-10-18 2012-10-18 Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII DK2768521T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548612P 2011-10-18 2011-10-18
EP11185650 2011-10-18
PCT/EP2012/070620 WO2013057171A1 (en) 2011-10-18 2012-10-18 Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii

Publications (1)

Publication Number Publication Date
DK2768521T3 true DK2768521T3 (da) 2016-10-24

Family

ID=48140373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12772969.7T DK2768521T3 (da) 2011-10-18 2012-10-18 Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII

Country Status (10)

Country Link
US (1) US9511123B2 (da)
EP (1) EP2768521B1 (da)
JP (1) JP6029674B2 (da)
KR (1) KR20140083035A (da)
CN (1) CN103889446B (da)
AU (1) AU2012318303B2 (da)
CA (1) CA2851057A1 (da)
DK (1) DK2768521T3 (da)
ES (1) ES2595160T3 (da)
WO (1) WO2013057171A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
PL3044231T3 (pl) * 2013-09-12 2021-01-11 Biomarin Pharmaceutical Inc. Wektory aav zawierające gen kodujący czynnik viii
DE102015107307B3 (de) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optisches Verfahren zur Gehaltsbestimmung von Hyaluronsäure
CN114929261A (zh) * 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
WO2024117476A1 (ko) * 2022-11-28 2024-06-06 주식회사 대웅제약 생체이용률이 개선된 니클로사마이드 함유 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
PL352060A1 (en) * 1999-06-12 2003-07-28 Merck Patent Gmbh Hialuronidase of hiarudinaria manillensis and method of separating, purifying and obtaining thereof by recombination
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ATE497783T1 (de) 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
RU2010149797A (ru) * 2008-05-06 2012-06-20 Октафарма АГ (CH) Комплекс
WO2010077294A1 (en) 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Centre Olfactory stem cells and uses thereof
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도

Also Published As

Publication number Publication date
CA2851057A1 (en) 2013-04-25
AU2012318303B2 (en) 2015-09-03
CN103889446B (zh) 2017-03-08
CN103889446A (zh) 2014-06-25
JP6029674B2 (ja) 2016-11-24
ES2595160T3 (es) 2016-12-28
AU2012318303A1 (en) 2013-05-02
JP2014532076A (ja) 2014-12-04
EP2768521B1 (en) 2016-07-13
US9511123B2 (en) 2016-12-06
WO2013057171A9 (en) 2014-04-03
EP2768521A1 (en) 2014-08-27
WO2013057171A1 (en) 2013-04-25
US20150023946A1 (en) 2015-01-22
KR20140083035A (ko) 2014-07-03

Similar Documents

Publication Publication Date Title
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
CN102387784B (zh) 冻干的重组vwf配方
DK2768521T3 (da) Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII
JP2017114889A (ja) 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
KR102444612B1 (ko) 재조합 산 알파-글루코시다제를 포함하는 제형
CN102046205A (zh) 具有延长的半衰期的因子ix缀合物
EP2768522B1 (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
JP2023123738A (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20210134642A (ko) 재조합 vwf (rvwf)를 이용한 예방 치료 방법
KR20220150303A (ko) 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료